GlassScriptPhysician profile
Kathy N Chism
NPI 1710929484
$7,582.90
in general payments reported to CMS, 2019-2025
46 companies · $1,493 in 2025
The $1,493 reported for 2025 was more than what 92% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,316 · 2020: $787 · 2021: $811 · 2022: $574 · 2023: $1,094 · 2024: $1,508 · 2025: $1,493.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,045 · Long Term Medical Supply Or Device Loan: $49.95.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,045.44 |
| Long Term Medical Supply Or Device Loan | $49.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,337.05 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $644.54 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $532.74 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $524.68 | 2019-2025 | Jardiance, Ofev |
| Amgen INC. | $495.78 | 2019-2025 | Repatha, Otezla, Repatha |
| Abbvie INC. | $480.84 | 2021-2025 | Vraylar |
| Glaxosmithkline, LLC. | $448.58 | 2019-2025 | Shingrix, Bexsero, Pediarix |
| Abbott Laboratories | $320.09 | 2021-2025 | Freestyle Libre 3, Freestyle Libre 2, Freestyle Insulinx |
| Lilly USA, LLC | $310.35 | 2019-2024 | Zepbound, Mounjaro, Jardiance |
| Merck Sharp & Dohme LLC | $260.75 | 2019-2024 | Belsomra, Gardasil 9, Pedvaxhib |
| Axsome Therapeutics, INC. | $208.26 | 2022-2025 | Auvelity |
| Janssen Pharmaceuticals, INC | $176.78 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $172.75 | 2019-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $147.23 | 2021-2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $137.98 | 2019-2021 |
Show all 46 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kathy Chism listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.